AlphaQuest LLC Acquires Shares of 2,426 Charles River Laboratories International, Inc. $CRL

AlphaQuest LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 2,426 shares of the medical research company’s stock, valued at approximately $368,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. increased its stake in Charles River Laboratories International by 109.3% in the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,481 shares of the medical research company’s stock valued at $680,000 after buying an additional 2,340 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Charles River Laboratories International in the 2nd quarter valued at about $56,000. Asset Management One Co. Ltd. increased its stake in Charles River Laboratories International by 9.1% in the 2nd quarter. Asset Management One Co. Ltd. now owns 1,625 shares of the medical research company’s stock valued at $247,000 after buying an additional 135 shares during the last quarter. Ethic Inc. increased its stake in Charles River Laboratories International by 107.0% in the 2nd quarter. Ethic Inc. now owns 7,420 shares of the medical research company’s stock valued at $1,113,000 after buying an additional 3,836 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its stake in Charles River Laboratories International by 1.2% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock valued at $1,072,000 after buying an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the transaction, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. The trade was a 3.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on CRL shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, October 8th. Citigroup raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price target for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Wall Street Zen cut shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 23rd. Finally, William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Eight analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $181.29.

Charles River Laboratories International Stock Down 0.6%

Charles River Laboratories International stock opened at $179.08 on Friday. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The firm has a market capitalization of $8.81 billion, a price-to-earnings ratio of -134.65, a P/E/G ratio of 4.83 and a beta of 1.50. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The firm has a 50 day simple moving average of $166.68 and a 200 day simple moving average of $152.14.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. During the same period in the previous year, the business earned $2.80 EPS. Charles River Laboratories International’s revenue was up .6% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).